Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

Ó¢ÎùÖÇÄÜÍê³É1.1ÒÚÃÀÔªEÂÖÈÚ×Ê£¬£¬£¬£¬£¬£¬¼ÓËÙAIÓë»úеÈËÇý¶¯µÄÒ©ÎïÑз¢Á¢Òì

2025-03-13
|
»á¼ûÁ¿£º

0314.jpgÒ½ÏßÒ©ÎÅ

1. 3ÔÂ13ÈÕ£¬£¬£¬£¬£¬£¬CDEÏÔʾ£¬£¬£¬£¬£¬£¬ÓÀÌ©ÉúÎ↑·¢µÄÀ©Ôö»î»¯µÄÁܰÍϸ°û£¨°®¿ÉÂØÈü×¢ÉäÒº£©ÄâÄÉÈëÓÅÏÈÉóÆÀ£¬£¬£¬£¬£¬£¬ÓÃÓÚÔ­·¢ÐÔ¸Îϸ°û°©¸ùÖÎÊõºó¸ß¸´·¢Î£º¦µÄ²¿·ÖÈËȺµÄÖÎÁÆ¡£¡£¡£

2. 3ÔÂ13ÈÕ£¬£¬£¬£¬£¬£¬·¼ÍØÉúÎïÐû²¼Æä×ÔÖ÷Ñз¢µÄÖØ×éÏÙÏà¹Ø²¡¶¾£¨rAAV£©»ùÒòÖÎÁƺòÑ¡²úÆ·FT-003×¢ÉäÒºÔٴλñÖйú¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©ÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬£¬£¬£¬ÄâÓÃÓÚÖÎÁÆÌÇÄò²¡ÊÓÍøÄ¤²¡±ä£¨Diabetic Retinopathy£¬£¬£¬£¬£¬£¬DR£©¡£¡£¡£

3. 3ÔÂ13ÈÕ£¬£¬£¬£¬£¬£¬CDEÍøÕ¾ÏÔʾ£¬£¬£¬£¬£¬£¬¿µÀÖÎÀÊ¿µÄÖØ×éÈý¼ÛÈËÈéÍ·Áö²¡¶¾£¨16/18/58ÐÍ£©ÒßÃ磨Èý¼ÛHPVÒßÃ磩ÄâÄÉÈëÓÅÏÈÉóÆÀ¡£¡£¡£

4. ¿ËÈÕ£¬£¬£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬£¬£¬°ÙʱÃÀÊ©¹ó±¦¹«Ë¾É걨µÄ1ÀàÐÂÒ©BMS-986489£¨BMS-986012 + nivolumabÀο¿¼ÁÁ¿¸´·½£©×¢ÉäÒº»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬£¬£¬£¬Ä⿪·¢ÖÎÁÆÐ¡Ï¸°û·Î°©£¨SCLC£©»¼Õß¡£¡£¡£ÕâÊÇÒ»¿î¿¹Fucosyl-GM1µ¥¿¹BMS-986012Ó뿹PD-1µ¥¿¹ÄÉÎäÀûÓȵ¥¿¹µÄÀο¿¼ÁÁ¿×éºÏ¡£¡£¡£

ͶÈÚÒ©ÊÂ

1. 3ÔÂ13ÈÕ£¬£¬£¬£¬£¬£¬Ó¢ÎùÖÇÄÜÐû²¼ÒÑÍê³ÉÓÉÑÇÖÞ×î´óµÄ×ÔÁ¦×ʲú¹ÜÀí¹«Ë¾Ö®Ò»»ÝÀí¼¯ÍÅ£¨HKG: 0806£©ÆìϵÄ˽ļ¹ÉȨ»ù½ð¡¢ÆÖ¶«´´Í¶ºÍÆÖ·¢¼¯ÍÅ¡¢Îý´´Í¶ºÍÒËÐ˹ú¿ØÁªºÏÁìͶµÄ1.1ÒÚÃÀÔªEÂÖÈÚ×Ê¡£¡£¡£

¿Æ¼¼Ò©ÑÐ

1. 3ÔÂ12ÈÕ£¬£¬£¬£¬£¬£¬Î¬ÂÞÄÉ´óѧVincenzo Corbo¡¢¸ñÀ­Ë¹¸ç´óѧPeter BaileyͨѶÔÚ¡¶Nature¡·½ÒÏþÂÛÎÄ¡°MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC¡±£¬£¬£¬£¬£¬£¬ÔÚÒÈÏÙ°©£¨PDAC£©Öз¢Ã÷ÁËȾɫÌåÍâ DNA£¨ecDNA£©µÄÖ÷Òª×÷Ó㬣¬£¬£¬£¬£¬ÎªÃ÷È·ÕâÖÖÖØ´ó¼²²¡´øÀ´ÁËеÄ˼Ð÷¡£¡£¡£

[1]Elena Fiorini et al., MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Nature (2025) Doi: https://doi.org/10.1038/s41586-025-08721-9

Ïà¹ØÐÂÎÅ
Ó¢ÎùÖÇÄÜ»ñD2ÂÖÈÚ×ÊÓÃÓÚAIÒ©ÎïÑз¢Ø­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ
2022-08-11
8ÔÂ10ÈÕ£¬£¬£¬£¬£¬£¬Ó¢ÎùÖÇÄܽñÌìÐû²¼»ñµÃD2ÂÖÈÚ×Ê¡£¡£¡£ÐÂÕÙļµÄDÂÖÈÚ×ʽ«½øÒ»²½Ö§³ÖÓ¢ÎùÖÇÄÜÍÆ½øÆäÄÚ²¿×ÔÑйÜÏߣ¬£¬£¬£¬£¬£¬°üÀ¨ÏÖÔÚÕýÔÚÐÂÎ÷À¼ºÍÖйúͬ²½¿ªÕ¹1ÆÚÁÙ´²ÊÔÑéµÄÁìÏÈÏîÄ¿£¬£¬£¬£¬£¬£¬ÒÔ¼°¼¸¸ö´¦ÓÚIND-Enabling½×¶ÎµÄÔÚÑйÜÏß¡£¡£¡£ËùÕÙļµÄ×ʽðÒ²½«ÓÃÓÚÓ¢ÎùÖÇÄÜÒªº¦ÐÔÕ½ÂԽṹ£¬£¬£¬£¬£¬£¬°üÀ¨½øÒ»²½¿ª·¢Æä¶Ëµ½¶ËÈ˹¤ÖÇÄÜÒ©ÎïÑз¢Æ½Ì¨Pharma.AI£» £» £»Íƶ¯È«×Ô¶¯»¯µÄÖÇÄÜ»úеÈËÒ©ÎïÑз¢ÊµÑéÊҺͻúеÈËÉúÎïÊý¾Ý¹¤³§µÄ½¨É裻 £» £»¼°Ö§³ÖÓ¢ÎùÖÇÄÜÔÚÈ«Çò¹æÄ£ÄÚµÄÇøÓòÖÐÐĽ¨Éè¡£¡£¡£
Ó¢ÎùÖÇÄÜÌØ·¢ÐÔ·ÎÏËά»¯ÐÂÒ©»ñFDA¹Â¶ùÒ©×ʸñØ­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ
2023-02-03
2ÔÂ3ÈÕ£¬£¬£¬£¬£¬£¬ÃÀ¸ß÷ÏàÖú¿Í»§Ó¢ÎùÖÇÄÜ£¨Insilico Medicine£©Ðû²¼£¬£¬£¬£¬£¬£¬¸Ã¹«Ë¾Ê׸öȫлúÖÆºòѡҩÎïINS018_055»ñµÃÃÀ¹úFDAÊÚÓèµÄ¹Â¶ùÒ©×ʸñ£¬£¬£¬£¬£¬£¬Ä⿪·¢ÓÃÓÚÖÎÁÆÌØ·¢ÐÔ·ÎÏËά»¯¡£¡£¡£INS018_055ÊÇÒ»¿î¾ßÓÐÈ«ÇòÊ×´´Ç±Á¦µÄС·Ö×ÓÒÖÖÆ¼Á¡£¡£¡£
Ó¢ÎùÖÇÄÜ×ÔÑп¹Ð¹ڿڷþÒ©»ñÅúÁÙ´²Ø­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ
2023-02-22
Ó¢ÎùÖÇÄÜ×ÔÖ÷Ñз¢µÄ¿¹Ð¹ڲ¡¶¾¿Ú·þÁ¢ÒìÒ©ISM3312ÒÑ»ñµÃÖйú¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖµÄÁÙ´²ÊÔÑéÔÊÐí¡£¡£¡£ISM3312ÊÇÒ»¿î°ÐÏòÖ÷ÂѰ×ø£¨3CLpro£©µÄ¸ßÑ¡ÔñÐÔС·Ö×ÓÒÖÖÆ¼Á£¬£¬£¬£¬£¬£¬¾ßÓиü¹ãÆ×µÄ¿¹¹Ú×´²¡¶¾»îÐÔ¡¢ÓÅÒìµÄµ¥Ò©¿Ú·þÉúÎïʹÓöȡ¢ÒÔ¼°Ç±ÔÚ¿¹ÁÙ´²ÄÍÒ©Í»±äµÄÄÜÁ¦¡£¡£¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿